PPD Pledges $5 Million to Rutgers' Ernest Mario School of Pharmacy
PPD, Inc. today announced the Mario Family Foundation has pledged $5 million to the Rutgers University Ernest Mario School of Pharmacy.
PPD Chairman of the Board Pledges $5 Million to Rutgers' Ernest Mario School of Pharmacy
WILMINGTON, N.C., Oct 29, 2008 (BUSINESS WIRE) -- PPD, Inc. (Nasdaq:PPDI) today announced the Mario Family Foundation has pledged $5 million to the Rutgers University Ernest Mario School of Pharmacy. Dr. Ernest Mario and his wife, Millie, established the foundation, and he serves as chairman of the board of directors at PPD.
The pledge was the largest individual gift during the university's 2007-2008 fiscal year and will be used to support graduate fellowships in the pharmacy school. Dr. and Mrs. Mario donated $5 million to the university's pharmacy school in 2001. The school was renamed the Ernest Mario School of Pharmacy that year.
"PPD CEO Fred Eshelman and I are fortunate to have the pharmacy schools we attended named in our honor--Fred at the University of North Carolina at Chapel Hill and I at Rutgers," Dr. Mario said. "Thanks to the success of PPD, and the hard work of its more than 10,500 employees globally, Fred and I have been given the opportunity to support pharmacy education and to encourage the continued health of our profession in a concrete and lasting way."
A 1961 graduate of Rutgers College of Pharmacy, Dr. Mario was awarded an honorary doctorate by Rutgers in 1992. He is chairman and chief executive officer of Capnia, Inc., a development-stage pharmaceutical company based in Palo Alto, Calif.
In 2007, the American Pharmacists Association awarded Dr. Mario its Remington Honor Medal, the highest accolade of the pharmacy profession. He has a longstanding record of educational philanthropy, having served as chairman of the American Foundation for Pharmaceutical Education and trustee of Duke University from 1989 to 2007, during which time he was chairman of the Duke University Health System.
PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 33 countries and more than 10,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients.
For more information, visit our Web site at http://www.ppdi.com.
SOURCE: PPD, Inc.
PPD, Inc.
Media:
Sue Ann Pentecost, +1-919-456-5890
sueann.pentecost@rtp.ppdi.com
or
Analysts/Investors:
Luke Heagle, +1-910-558-7585
luke.heagle@wilm.ppdi.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
